Related Experiment Video
Updated: Mar 1, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
[Risk factors for developing thromboembolic complications in oncological patients (a literature review)]
A N Kulikova1, A A Tonkacheva1
1Saratov State Medical University named after V.I. Razumovsky of the Ministry of Health of the Russian Federation, 410000, Saratov, Russian Federation.
None:
Oncological patients are typically prone to the development of thromboembolic complications significantly worsening the general prognosis of the disease. Therefore, determining the probability of the onset and prevention of these complications remains an important practical task. This literature review presents the data of foreign and Russian authors on the major risk factors for developing venous thromboembolic complications in oncological patients, also giving characteristics of the main biochemical markers of the ongoing processes and intrinsic thereto alterations. This is followed by reflecting the incidence of thromboembolic events depending on the type, localization, incidence, degree of differentiation of malignant neoplasms, the presence or absence of concomitant diseases in patients, as well as the main demographic criteria associated with this pathology, Also analyzed herein is the effect of some chemotherapeutic drugs used as adjuvant and neoadjuvant therapy on the onset of thrombotic events. Next comes the information on the effect of radiation methods of treatment on the development of thromboses and thromboembolisms in oncological patients. Additionally demonstrated is the relationship of thromboembolic processes in patients suffering from malignant neoplasms with surgical interventions and placement of central venous catheters.
Related Concept Videos
Venous Thrombosis IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis I: Introduction
Pulmonary Embolism III: Nursing Management
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
